Inactive Instrument

Lonza Group AG Share Price Swiss Exchange

Equities

CH0013841017

Biotechnology & Medical Research

End-of-day quote Swiss Exchange
- CHF - Intraday chart for Lonza Group AG

Financials

Sales 2024 * 6.65B 7.35B 613B Sales 2025 * 7.5B 8.29B 692B Capitalization 37.47B 41.39B 3,456B
Net income 2024 * 904M 998M 83.37B Net income 2025 * 1.11B 1.23B 103B EV / Sales 2024 * 5.96 x
Net Debt 2024 * 2.18B 2.4B 201B Net Debt 2025 * 2.47B 2.73B 228B EV / Sales 2025 * 5.32 x
P/E ratio 2024 *
42 x
P/E ratio 2025 *
33.7 x
Employees -
Yield 2024 *
0.87%
Yield 2025 *
1%
Free-Float 95.87%
More Fundamentals * Assessed data

Latest transcript on Lonza Group AG

Managers TitleAgeSince
Chief Executive Officer 72 25/17/25
Director of Finance/CFO 52 01/21/01
Chief Operating Officer 55 01/22/01
Members of the board TitleAgeSince
Director/Board Member 63 16/14/16
Director/Board Member 66 16/14/16
Director/Board Member 58 05/22/05
More insiders
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company